Escherichia (e.g., E. Coli, Etc.) Patents (Class 435/252.33)
-
Publication number: 20150111222Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.Type: ApplicationFiled: August 8, 2012Publication date: April 23, 2015Applicant: HOWARD hUGHES MEDICAL INSTITUTEInventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
-
Publication number: 20150111249Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a.) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b.) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti Fc Rn antibodies and proteins made by the methods described herein.Type: ApplicationFiled: May 13, 2013Publication date: April 23, 2015Inventors: Philip Jonathan Bassett, David Paul Humphreys, Pareshkumar Manjibhai Patel
-
Publication number: 20150111821Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.Type: ApplicationFiled: October 21, 2014Publication date: April 23, 2015Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
-
Publication number: 20150110781Abstract: The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.Type: ApplicationFiled: May 24, 2012Publication date: April 23, 2015Inventors: Enyun Shen, Shiqi Ren
-
Publication number: 20150110720Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.Type: ApplicationFiled: September 25, 2014Publication date: April 23, 2015Applicant: STC.UNMInventors: ANATOLIY MARKIV, RAVI VENKATA DURVASULA, ANGRAY SINGH KANG
-
Patent number: 9012195Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.Type: GrantFiled: July 17, 2013Date of Patent: April 21, 2015Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20150104458Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: August 26, 2014Publication date: April 16, 2015Applicant: Biomay AGInventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20150105315Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique IndustrielleInventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
-
Publication number: 20150104853Abstract: Provided herein are improved compositions and methods for the increased production of isoprene. Also provided herein are improved compositions and methods for the increased production of heterologous polypeptides capable of biological activity.Type: ApplicationFiled: October 7, 2014Publication date: April 16, 2015Inventors: Zachary Q. BECK, Marguerite A. Cervin, Alex T. Nielsen, Caroline M. Peres
-
Publication number: 20150104452Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: June 10, 2014Publication date: April 16, 2015Inventors: Tariq Ghayur, Edward B. Reilly, Andrew Phillips, Randy L. Bell, Yingchun Li, Hua Ying, Susan E. Morgan-Lappe, Gillian A. Kingsbury, Jieyi Wang, Suzanne M. Norvell, Junjian Liu
-
Publication number: 20150104457Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.Type: ApplicationFiled: June 25, 2013Publication date: April 16, 2015Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
-
Publication number: 20150105326Abstract: The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by using a methyl degron peptide or a methyl degron gene.Type: ApplicationFiled: October 11, 2013Publication date: April 16, 2015Applicant: Seoul National University (SNU) R&D FoundationInventor: Sung Hee BAEK
-
Publication number: 20150104851Abstract: The present invention relates to novel mutants with cyclase activity and use thereof in a method for biocatalytic cyclization of terpenes, such as in particular for the production of isopulegol by cyclization of citronellal; a method for the preparation of menthol and methods for the biocatalytic conversion of further compounds with structural motifs similar to terpene.Type: ApplicationFiled: December 4, 2014Publication date: April 16, 2015Inventors: Michael Breuer, Bernhard Hauer, Dieter Jendrossek, Gabrielle Siedenburg, Juergen Pleiss, Demet Sirim, Silvia Racolta
-
Publication number: 20150105537Abstract: A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in E. Coli.Type: ApplicationFiled: March 28, 2013Publication date: April 16, 2015Applicant: BIOGENOMICS LIMITEDInventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
-
Patent number: 9005953Abstract: This invention relates to a recombinant microorganism having improved butanol production capacity and butanol production with the use of such recombinant microorganism with good efficiency. In this invention, the acetoacetyl-CoA synthase gene encoding an enzyme capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and a group of genes involved in butanol biosynthesis that enables synthesis of butanol from acetoacetyl-CoA are introduced into a host microorganism.Type: GrantFiled: May 6, 2010Date of Patent: April 14, 2015Assignee: Toyota Jidosha Kabushiki KaishaInventors: Masayoshi Muramatsu, Shusei Obata, Satoshi Yoneda, Masahiro Sugimura, Tomohisa Kuzuyama
-
Patent number: 9005939Abstract: The present invention relates to an isolated, recombinant or synthetic polynucleotide encoding a polypeptide with protoilludene synthase activity and comprising a sequence selected from the group consisting of a) SEQ ID Nos. 1 or 14 of the attached sequence listing; b) a nucleic acid sequence complementary to SEQ ID Nos. 1 or 14; c) nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequences defined in a) and b) or their complementary strands, as well as to the polypeptide encoded by the isolated polynucleotide, as well as a method for the production of melleolides employing the polynucleotide or polypeptide of the invention.Type: GrantFiled: January 31, 2013Date of Patent: April 14, 2015Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Stefan Jennewein, Benedikt Engels, Torsten Grothe, Marc Stadler
-
Publication number: 20150099283Abstract: A method of producing patchoulol and 7-epi-?-selinene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). The method may be carried out in vitro or in vivo to produce patchoulol and 7-epi-?-selinene, compounds which can be useful in the field of perfumery.Type: ApplicationFiled: December 19, 2014Publication date: April 9, 2015Applicant: FIRMENICH SAInventors: Michel SCHALK, Fabienne DEGUERRY
-
Publication number: 20150099298Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: May 8, 2013Publication date: April 9, 2015Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
-
Publication number: 20150099861Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.Type: ApplicationFiled: September 12, 2012Publication date: April 9, 2015Applicant: GENZYME CORPORATIONInventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
-
Publication number: 20150098945Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenic effects in in-vivo models.Type: ApplicationFiled: April 26, 2013Publication date: April 9, 2015Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
-
Publication number: 20150099282Abstract: The present invention relates to a polypeptide comprising the amino acid sequence of the Bacillus subtilis alanine dehydrogenase or a variant thereof, where Leu197 or an amino acid which is located at a homologous position in the amino acid sequence is exchanged for an amino acid with a positively charged side chain, to a nucleic acid molecule encoding such a polypeptide, and to a process for the production of alanine or a compound generated with consumption of alanine, comprising the step of reacting pyruvate with ammonium and NADPH to give alanine by bringing the pyruvate into contact with the polypeptide according to the invention or with the cell according to the invention.Type: ApplicationFiled: April 16, 2013Publication date: April 9, 2015Applicant: EVONIK INDUSTRIES AGInventors: Thomas Haas, Jan Christoph Pfeffer, Arne Skerra, Alexandra Lerchner, Alexander Jarasch
-
Publication number: 20150098956Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
-
Publication number: 20150099705Abstract: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Mack FLINSPACH, Alan Wickenden, Ross Fellows, Robert Neff, Yi Liu, Rebecca Hagan, Qinghao Xu
-
Publication number: 20150099271Abstract: Disclosed herein are fluorescent proteins and Split-Fluorescent proteins (SFPs) including Split-Green Fluorescent Proteins, such as tripartite split-GFPs. Nucleic acid molecules encoding the fluorescent proteins and SFPs, as well as methods of using the fluorescent proteins and SFPs, are also disclosed. For example, methods of detecting protein-protein interactions are disclosed herein.Type: ApplicationFiled: October 6, 2014Publication date: April 9, 2015Inventors: Geoffrey Waldo, Stephanie Cabantous
-
Publication number: 20150098908Abstract: The invention relates to the field of medicine. In particular, it relates to recombinant cationic polypeptides and their use as biolubricant. Provided is a biolubricant substance comprising the amino acid sequence[(GKGVP)9]n, wherein n is ?5.Type: ApplicationFiled: October 4, 2013Publication date: April 9, 2015Applicants: ACADEMISCH ZIEKENHUIS GRONINGEN, RIJKSUNIVERSITEIT GRONINGENInventors: PRASHANT KUMAR SHARMA, ANDREAS HERRMANN, ANKE KOLBE, DEEPAK HALENAHALLY VEEREGOWDA
-
Publication number: 20150099278Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: December 19, 2014Publication date: April 9, 2015Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
-
Patent number: 8999691Abstract: Disclosed is a modified glucose dehydrogenases that has dramatically increased productivity in Escherichia coli and dramatically increased thermal stability, which is obtained by introducing specific amino acid mutations to glucose dehydrogenase derived from Botryotinia fuckeliana. Also disclosed is a modified glucose dehydrogenases that has dramatically increased productivity in E. coli and dramatically increased thermal stability, which is obtained by replacing two amino acid residues in glucose dehydrogenase of fungal origin with cysteine residues. The novel glucose dehydrogenase has a low reactivity to xylose.Type: GrantFiled: June 29, 2011Date of Patent: April 7, 2015Assignee: Ultizyme International Ltd.Inventors: Koji Sode, Kazushige Mori
-
Patent number: 8999343Abstract: Myostatin antagonists, including myostatin binding antibodies, are disclosed. Also disclosed are nucleic acids encoding and cells including myostatin antagonists; methods of production; and methods of use.Type: GrantFiled: August 15, 2011Date of Patent: April 7, 2015Assignee: Amgen Inc.Inventors: Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou
-
Patent number: 8999682Abstract: Disclosed are the uses of specific genes of the mevalonate and isoprenoid biosynthetic pathways, and of inactive gene sites (the pseudogene) to (1) enhance biosynthesis of isopentenyl diphosphate, dimethylallyl diphosphate and isoprenoid pathway derived products in the plastids of transgenic plants and microalgae, (2) create novel antibiotic resistant transgenic plants and microalgae, and (3) create a novel selection system and/or targeting sites for mediating the insertion of genetic material into plant and microalgae plastids. The specific polynucleotides to be used, solely or in any combination thereof, are publicly available from GeneBank and contain open reading frames having sequences that upon expression will produce active proteins with the following enzyme activities: (a) acetoacetyl CoA thiolase (EC 2.3.1.9), (b) 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase (EC 4.1.3.5), (c) HMG-CoA reductase (EC 1.1.1.34), (d) mevalonate kinase (EC 2.7.1.36), (e) phosphomevalonate kinase (EC 2.7.4.Type: GrantFiled: November 21, 2013Date of Patent: April 7, 2015Assignees: Danisco US Inc., Kuehnle Agrosystems Company LLCInventors: Frederick M. Hahn, Adelheid R. Kuehnle
-
Publication number: 20150093395Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20150093803Abstract: A nitrile hydratase variant of the present invention comprises substitution of at least one amino acid with another amino acid to improve two or more properties of nitrile hydratase by substitution of one amino acid.Type: ApplicationFiled: September 19, 2014Publication date: April 2, 2015Applicant: Mitsui Chemicals, Inc.Inventors: Kazuya Matsumoto, Yasushi Kazuno, Daisuke Mochizuki, Junko Tokuda
-
Publication number: 20150093387Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: August 22, 2014Publication date: April 2, 2015Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
-
Publication number: 20150093795Abstract: The present invention relates tocutinasevariants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: April 30, 2013Publication date: April 2, 2015Inventors: Aditya Basu, Naik Sangeeta, Santhosh Mepadam Vasu, Paul Pritish, Rakhi Saikia, Allan Svendsen
-
Publication number: 20150094236Abstract: A selectively inducible, single-stranded DNA (ssDNA) expression library, a method for constructing a ssDNA expression library, a method for screening ssDNA using the expression library, and a method for identifying ssDNA molecules that alter expression of bacterial and fungal gene(s) related to cell growth and toxin production and secretion. The screening library is used to, among other things, identify ODNs effective in stopping cell growth, killing bacteria or fungi, or preventing bacteria and/or fungi from synthesizing and secreting their toxins, and/or to discover ODNs effective in eukaryotic (e.g., mammalian) cells for targeted alteration of gene function. The library is also useful for identifying ssDNAs or ODNs that are used as therapeutic agents for, for instance, providing a method for treatment of bacterial infections such as sepsis.Type: ApplicationFiled: October 27, 2014Publication date: April 2, 2015Applicant: Star Biologics, Inc.Inventors: Yin Chen, Xin Xing Tan
-
Publication number: 20150093388Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.Type: ApplicationFiled: August 29, 2014Publication date: April 2, 2015Applicant: ImmunoGen, Inc.Inventors: Olga AB, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
-
Publication number: 20150093792Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 24, 2014Publication date: April 2, 2015Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
-
Publication number: 20150094271Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventors: Jung-Hoon Lee, Eunji Kang, Hye Yoon Kang, Dongkyu Shin, Jae Il Lee, Jieun Han, Jung Min Lee
-
Publication number: 20150093781Abstract: The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism.Type: ApplicationFiled: August 13, 2014Publication date: April 2, 2015Inventors: Michael Schilling, Christine Lang, Andreas Raab
-
Publication number: 20150094450Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.Type: ApplicationFiled: February 27, 2013Publication date: April 2, 2015Applicants: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA BASIC SCIENCE INSTITUTEInventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
-
Publication number: 20150093357Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Applicant: UNIVERSITY OF CONNECTICUTInventors: Leo Lefrancois, Thomas A. Stoklasek
-
Publication number: 20150093798Abstract: A microorganism capable of producing 1,4-butanediol and a method of producing 1,4-butanediol using the same.Type: ApplicationFiled: September 29, 2014Publication date: April 2, 2015Inventors: Yukyung Jung, Kwangmyung Cho, Jinhwan Park, Hwayoung Cho
-
Publication number: 20150093790Abstract: The disclosure provides thermostable enzymes isolated from Caldicellulosiruptor bescii and fragments thereof useful for the degradation of cellulose and/or hemicellulose, including thermostable cellulases and hemicellulases. The disclosure further provides nucleic acids encoding the thermostable enzymes of the disclosure. The disclosure also provides methods for the conversion of cellulose and hemicellulose into fermentable sugars using thermostable enzymes of the disclosure. The disclosure also provides enzyme cocktails containing multiple enzymes disclosed herein. The enzymes can be used to release sugars present in cellulose or hemicellulose for subsequent fermentation to produce value-added products.Type: ApplicationFiled: December 20, 2011Publication date: April 2, 2015Applicant: The Board pf Trustees of the University of IllinoisInventors: Yejun Han, Xiaoyun Su, Dylan Dodd, Roderick I. Mackie, Issac K.O. Cann
-
Patent number: 8993285Abstract: A non-naturally occurring microbial organism having an isopropanol pathway includes at least one exogenous nucleic acid encoding an isopropanol pathway enzyme. The pathway includes an enzyme selected from a 4-hydroxybutyryl-CoA dehydratase, a crotonase, a 3-hydroxybutyryl-CoA dehydrogenase, an acetoacetyl-CoA synthetase, an acetyl-CoA:acetoacetate-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetate decarboxylase, and an acetone reductase. A non-naturally occurring microbial organism having an n-butanol pathway includes at least one exogenous nucleic acid encoding an n-butanol pathway enzyme. Other non-naturally occurring microbial organism have n-butanol or isobutanol pathways. The organisms are cultured to produce isopropanol, n-butanol, or isobutanol.Type: GrantFiled: April 30, 2010Date of Patent: March 31, 2015Assignee: Genomatica, Inc.Inventor: Anthony P. Burgard
-
Patent number: 8993305Abstract: The invention provides for methods for the production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in cells via the heterologous expression of phosphoketolase enzymes.Type: GrantFiled: October 5, 2012Date of Patent: March 31, 2015Assignees: Danisco US Inc., The Goodyear Tire & Rubber CompanyInventors: Zachary Q. Beck, Andrew C. Eliot, Caroline M. Peres, Dmitrii V. Vaviline
-
Patent number: 8993276Abstract: Nucleic acid molecules encoding chimeric cellulase polypeptides that exhibit improved cellulase activities are disclosed herein. The chimeric cellulase polypeptides encoded by these nucleic acids and methods to produce the cellulases are also described, along with methods of using chimeric cellulases for the conversion of cellulose to sugars such as glucose.Type: GrantFiled: July 12, 2013Date of Patent: March 31, 2015Assignee: Alliance for Sustainable Energy, LLCInventors: Qi Xu, John O. Baker, Michael E. Himmel
-
Patent number: 8993743Abstract: The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein.Type: GrantFiled: February 18, 2011Date of Patent: March 31, 2015Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Guido Meurer, Esther Gabor, Anke Bachert, Jürgen Eck
-
Publication number: 20150086558Abstract: Antibodies binding to junction regions between the CH4 and C?mX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicant: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Chien-Jen Lin, Nien-Yi Chen
-
Publication number: 20150086538Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.Type: ApplicationFiled: April 11, 2013Publication date: March 26, 2015Inventor: Roland Beckmann
-
Publication number: 20150087573Abstract: Described are compositions and methods relating to variant alpha-amylasess having altered biochemical properties and advantageous performance characteristics as compared to a reference alpha-amylase. The variants are suitable for use in various industrial applications such as starch conversion, ethanol production, laundry, dishwashing, pulp and paper production, textile desizing, and/or sweetener production.Type: ApplicationFiled: August 28, 2014Publication date: March 26, 2015Applicant: Danisco US Inc.Inventors: David A. Estell, Brian E. Jones, Marc Kolkman, Christian D. Adams, Edward M. Concar
-
Publication number: 20150087604Abstract: The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity.Type: ApplicationFiled: April 16, 2012Publication date: March 26, 2015Inventors: Xiaodong Zhang, Lihong Ye